Medicines Formulary

Medicines A–Z

R

Drug name	NICE TAs	Comments
Rabies immunoglobulin
Radium-223 (Xofigo®)	TA412 - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	Hospital only - NHSE commissioned
Ralititrexed injection		Hospital use only
Raloxifene tablets	TA160 - Osteoporosis - secondary prevention including strontium ranelate TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramipril capsules		Ramipril (as capsules) has the most robust evidence base and is considered to be the first line agent of choice.
Ranibizumab injection	TA294 - Aflibercept solution for injection for treating wet age-related macular degeneration TA297 - Ocriplasmin for treating vitreomacular traction TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranolazine M/R		Consultant to initiate and stabilise patient before GP takes over prescribing
Rasagiline		ESCA
Rasburicase injection
Raviciti (Glycerol phenylbutyrate liquid)

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.